[Physical and other methods therapy of the spasticity in children].
BACKGROUND
Spasticity is a very bothering symptom, which aggravates disability and prevents in many cases a successful treatment.


OBJECTIVE
The aim of this paper was to remind different methods of treatment of spasticity, with a special attention to neurorehabilitation.


RESULTS
In the research the complex pathogenesis of spasticity was referred, as well as factors influenced its aggravation and associated symptoms. Methods of evaluation of degree of spasticity were also recalled. The advantage and disadvantage of neurorehabilitation were also discussed. NDT-Bobath method as well as other kinesiotherapy methods were described with the necessity to make individualised program. The methods of rehabilitation which help in the reduction of muscle tone were refered, as well as the importance of botulin toxin, in the context of lack of efficacy of drugs in the reduction of spasticity, which cannot in fact help to reach better results of rehabilitation. The effectiveness of spasticity therapy with baclofen pump and other surgical methods were also mentioned.


CONCLUSIONS
The decision to treat spasticity must be justified and depended on its intensity. It is necessary to develop new methods to obtain the durable effect of therapy of spasticity.
Swierczyńska
Anna
A
Klinika Neurologii Dzieciecej, Uniwersytet Jagielloński Collegium Medicum, Kraków. neupedkr@cm-uj.krakow.pl
Renata
Kłusek
K
Jaworek
Magdalena
M
D001418:Baclofen / Q000008:administration & dosage; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage; D002547:Cerebral Palsy / Q000150:complications; D002648:Child; D004334:Drug Administration Schedule; D006801:Humans; D015918:Infusion Pumps, Implantable; D009125:Muscle Relaxants, Central / Q000008:administration & dosage* / Q000009:adverse effects; D009128:Muscle Spasticity / Q000188:drug therapy / Q000628:therapy*; D009465:Neuromuscular Agents; D026741:Physical Therapy Modalities
D009125:Muscle Relaxants, Central; D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A; D001418:Baclofen